We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
In the latest close session, Humacyte, Inc. (HUMA - Free Report) was down 4.14% at $1.62. This move lagged the S&P 500's daily loss of 0.99%. Meanwhile, the Dow experienced a drop of 0.23%, and the technology-dominated Nasdaq saw a decrease of 1.58%.
Coming into today, shares of the company had lost 3.98% in the past month. In that same time, the Medical sector gained 6.65%, while the S&P 500 gained 3.59%.
Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.17, signifying a 48.48% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.35 per share and revenue of $3.51 million, indicating changes of +66.67% and 0%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Humacyte, Inc. should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Currently, Humacyte, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 93, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest close session, Humacyte, Inc. (HUMA - Free Report) was down 4.14% at $1.62. This move lagged the S&P 500's daily loss of 0.99%. Meanwhile, the Dow experienced a drop of 0.23%, and the technology-dominated Nasdaq saw a decrease of 1.58%.
Coming into today, shares of the company had lost 3.98% in the past month. In that same time, the Medical sector gained 6.65%, while the S&P 500 gained 3.59%.
Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.17, signifying a 48.48% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.35 per share and revenue of $3.51 million, indicating changes of +66.67% and 0%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Humacyte, Inc. should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Currently, Humacyte, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 93, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.